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Abstract Human pharmaceutical active ingredients that are
orally or parenterally administered may be metabolised in the
body and after excretion may be further transformed in the
receiving environmental compartments. The optimal outcome
from an environmental point of view—complete mineralisation
—is rarely observed. Small molecule pharmaceuticals are com-
monly not readily biodegradable according to Organisation for
Economic Cooperation and Development (OECD) 301 tests.
However, primary transformation is often observed. To gain
information on the transformation of active ingredients in the
environment, long-term studies like transformation in aquatic
water/sediment systems according to OECD guideline 308 are
required for the environmental risk assessment for human active
pharmaceutical ingredients. Studies received until mid 2010 as
part of the dossiers formarketing authorisation applicationswere
evaluated concerning transformation products. The evaluation
revealed that in 70 % of the studies, at least one transformation
product (TP) is formed above 10 % of the originally applied
dose, but in only 26 % of the studies are all TP identified. The
evaluation also revealed that some TP of pharmaceutical active
ingredients show a considerably longer DT50 compared to the
parent compound. An example is the TP (val)sartan acid that is
formed from an antihypertensive compound.
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Introduction
Human pharmaceutical active ingredients (AI) are being
consumed in increasing amounts worldwide. The high
amounts consumed combined with the desired stability and
resulting persistency of the compounds have led to their
ubiquitous presence in water bodies (Hughes et al. 2013).
This has triggered concerns about the ecotoxicological ef-
fects and the potential for the contamination of groundwater
and raw drinking water. Therefore, since 2001, an assess-
ment of environmental fate and effects is a mandatory part of
the procedure for the marketing authorisation for human
pharmaceuticals (EC 2001). The assessment is based on
estimating the exposure of the environment and on experi-
mental studies to characterise the fate and effects of pharma-
ceutical AI in the environment (EMA 2006).
The most common pathway into the environment for human
pharmaceutical AI after usage by patients is via excretion,
subsequent transport to a wastewater treatment plant (WWTP)
and entry into the environment via the WWTP effluent or via
spreading of sewage sludge on agricultural areas or its use in
other open applications. Additionally, AI from topical formula-
tions (e.g. gels, crèmes, etc.) and AI emitted from production
and formulation facilities also contribute to the pharmaceutical
compounds introduced into the environment (Fick et al. 2009;
Phillips et al. 2010; Sanchez et al. 2011). During their use and
their subsequent entry into the aquatic or terrestrial environ-
ment, AI are subject to metabolism and transformation. In the
patient, the parent compound may be metabolised into phase I
or phase II metabolites (ME). For many AI, a high fraction of
the administered dose is excreted as mineralisation is rarely
observed and accumulation of AI or its ME in the patient is (in
most cases) not desired. During sewage treatment, further trans-
formation may take place. The resulting mixture of the parent
compound, ME and transformation products (TP) reaches
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different environmental compartments (e.g. rivers, lakes, sedi-
ment, soil) with either the sewage plant effluent or the spreading
of sewage sludge onto land, where further transformation oc-
curs including biotransformation and abiotic transformations
like, e.g. phototransformation.
Depending on their sorption and biodegradation properties
and the amount that is consumed, many pharmaceutical AI are
not or only partly removed by conventional wastewater treat-
ment technologies (Joss et al. 2006). Pharmaceuticals are just
now starting to be incorporated into routine monitoring
programmes for surface waters (EC 2012), but despite this
lack of consistent monitoring efforts, it becomes clear from
many studies that pharmaceutical AI and their ME and TP are
widely detected in surface water and in some cases also in
groundwater or raw water for drinking water production
(Ternes 1998; Heberer 2002; Kolpin et al. 2002; Bergmann
et al. 2011; Hughes et al. 2013).
ME and transformation products are covered in the envi-
ronmental risk assessment by the so-called total residue ap-
proach (EMA 2006). This approach assumes that the parent
compound, ME and TP show the same behaviour and effects
in the environment. In many cases, this approach might be
valid, but in some cases, the ME or TP actually might be of
higher concern than the parent compound, and therefore,
further information is required to comprehensively conduct
an environmental risk assessment. ME or TP might be of
higher (eco-)toxicological concern than the parent. Strategies
to deal with this concern have been described (Escher et al.
2006; Escher and Fenner 2011). However, if TP are of concern
because they are more persistent and/or more mobile than the
parent compounds cannot be covered by the proposed testing
scheme. Information on the persistence of a TP should be
available from simulation type studies conducted as part of the
environmental risk assessment, e.g. studies on transformation
in water/sediment systems according to Organisation for
Economic Cooperation and Development (OECD) guideline
308. Additionally, information on the mobility of the TP, e.g.
their adsorption/desorption behaviour in relevant matrices, is
required to estimate their risk for groundwater or raw drinking
water contamination. It is important to know the identity of the
respective ME or TP to be able to include it into monitoring
programmes. Currently, for human pharmaceutical AI that are
not readily biodegradable according to tests following OECD
guideline 301, more detailed studies on transformation in
water/sediment systems according to OECD guideline 308
have to be conducted (EMA 2006; OECD 2002). The guide-
line requires screening for TP, to quantify their amount, to
determine the DT50 (time required until 50 % of the substance
has dissipated) and to identify the TP that are formed at more
than 10 % of the applied dose.
The aim of this study was to evaluate information from
the environmental risk assessment for human pharmaceutical
AI concerning biodegradability and transformation in
water/sediment systems. Studies conducted according to
OECD guideline 301 on ready biodegradability (OECD
1992) and OECD 308 on transformation in water/sediment
systems (OECD 2002) were analysed.
First, an overview was gained on how often TP are ob-
served in these studies. Furthermore, the quality of studies
concerning detection, quantification, identification and de-
termination of DT50 for TP was evaluated. Additionally, it
was studied whether TP are just transient phenomena or if
there are indications of a longer persistence in the environ-
ment compared to the parent compounds. Emphasis was put
on identifying specific problems that complicate the inter-
pretation of results from OECD 308 studies from pharma-
ceutical AI. A comparison of results from OECD 301 tests
on determining ready biodegradability and results from
OECD 308 water/sediment systems was also conducted.
Based on the different evaluations, recommendations for
conducting transformation studies for the aquatic environ-
ment are derived together with conclusions for the assess-
ment of the fate and effects of TP in the environmental risk
assessment of pharmaceutical AI.
Materials and methods
The evaluation is based on all available OECD 301 and
OECD 308 type studies that have been submitted up to mid
2010 as part of the dossiers for marketing authorization appli-
cations as required according to EMA (2006). The OECD 301
guideline describes several methods to determine ready bio-
degradability of substances. For human pharmaceutical AI,
the OECD 301 B test is recommended (EMA 2006) as it
delivers unambiguous results on mineralisation and circum-
vents problems which might arise due to sorption of analytes
to test vessels. In the test, diluted activated sludge from a
wastewater treatment plant is incubated with (unlabelled) test
substance, and the CO2 evolution is measured and compared
to the theoretical maximal CO2 evolution expected for the test
compound, corrected for the CO2 evolution observed in blank
samples. A substance is classified as readily biodegradable if
after 28 days more than 60 % of the theoretically observable
CO2 has formed.
The OECD 308 guideline describes a simulation test used
to assess the transformation of chemicals in the environment.
Details can be found in OECD (2002). Briefly, the test in-
volves incubation of a (radio-labelled) test substance, e.g. a
pharmaceutical AI, in a test vessel filled with sediment and
water at a ratio of 1:3 to 1:4 (v/v) sampled from the same
location from either a river or a lake. The test setup according
to the guideline consists of four different systems, two aero-
bic and two anaerobic systems. For pharmaceuticals, infor-
mation on anaerobic systems is usually not received
(EMA 2010); therefore, only aerobic studies were evaluated.
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The test sediments have to fulfil specific criteria concerning
their organic carbon content and texture, and the test system
has to be characterised concerning pH, particle size distribu-
tion, TOC, microbial biomass and redox potential. The test
substance is added to the water phase of the system, and
incubation is started. Parameters measured are the partitioning
of the test substance (and TP) between water and sediment,
mineralisation of the test substance (only if radio labelled),
non-extractable residues in the sediment (only if radio la-
belled), the amount of test substance and TP at different
sampling time points. A screening for the formation of TP
has to be included, and detected TP have to be quantified. TP
present at or above 10 % of the initially applied dose or those
that do not show a clearly decreasing behaviour in the end of
the study have to be identified. Additionally, by fitting an
appropriate kinetic model to the data points, DTx (usually
DT50 and DT90) for the parent or the TP should be derived
(FOCUS 2006).
First, the reports were evaluated whether the labelling
position of the radiolabel was given in a comprehensible
way. Incomplete study reports and cited literature were
discarded. The remaining 33 studies were searched for in-
formation on screening for TP, detection, quantification,
identification, and DTx values of TP. The total number of
detected TP was recorded, as well as the number of TP
present more than once at or above 10 % of the originally
applied dose (of radioactivity) for the parent compound.
Here also, TP were included that were present at increasing
concentrations towards the end of the study. Additionally, the
DT50 of the parent and the TP were compared, to identify TP
that are longer lived than the respective parent compound.
Comparisons were made compartment specific, where pos-
sible. In case only a DT50 for the total system was available,
the comparison was based on that value. For the comparison
in between OECD 308 and 301 results, mineralisation (CO2
evolution) on day 28 (or the closest measured day (±2 days))
was recorded fromOECD 308 studies and from the correspond-
ing studies according to OECD 301 on ready biodegradability.
Results
Ready biodegradability
Tests according to the OECD guideline 301 B are suitable to
assess the potential of pharmaceutical AI to readily biode-
grade. Commonly, only low amounts of mineralisation to
CO2 are observed, and AI have to be classified as not readily
biodegradable. This was true for all considered small mole-
cule AI. In this article, the termAI refers subsequently to small
molecule AI; biologicals were not evaluated. For 29 different
AI, the experiments most often report 0 % mineralisation
(negative results are set to 0 %). Therefore, the median of
the 29 studies is 0 %. The mean is 4 % and the maximal
mineralisation observed is 20 % CO2 evolution.
The low mineralisation commonly observed is in accor-
dance with previous findings (Trautwein and Kümmerer
2011; Al-Ahmad et al. 1999). This is not surprising, as
pharmaceutical AI are designed to be metabolically stable
and thus persistent substances (Nassar et al. 2004). However,
the test on ready biodegradability is very useful in excluding
AI which are biodegradable and can thus relatively easily be
classified as not persistent (like, e.g. many biological AI).
However, to assess the persistence of pharmaceutical AI
in the environment, simulation studies on transformation of
the test substance in environmental compartments like soil,
water or water/sediment systems are crucial.
Occurrence of TP
In all studies in water/sediment systems except for those
which did not explicitly contain any information on TP (n=
2), TP were detected. The median of the number of detected
TP for all studies is 3, ranging from 1 to 45. It is important to
note that the actual number of formed TP is very likely
greater than the number deducible from the reports as (1)
TP often cannot be detected due to an unsuitable or not
representative labelling position as AI are often complex
molecules (see also comparison 301/308 results below), (2)
TP below 10% are often only summarily treated as “some” or
“a few” and have not been counted and (3) only the number of
detected peaks is reported. One peak can consist of more than
one substance, especially if only low-resolution analytical
techniques like thin-layer chromatography are used.
Identification of TP
In 70 % of studies (n=22), at least one TP ≥10 % was
detected. It was attempted in 52 % of the studies (n=16) to
identify at least one of the TP ≥10 %. However, in only eight
studies (26 %) were all TP ≥10 % identified. Detailed infor-
mation on detection and attempts on identification of TP in
studies conducted according to OECD guideline 308 in
water/sediment systems can be found in Fig. 1. Only in about
a quarter of all studies are the requirements according to
OECD guideline 308 fully met. In a majority of studies, no
or only partial information on the identity of TP formed in
amounts exceeding 10 % of the originally applied dose is
available.
For identification purposes, mostly LC–MS/MS was
used. In some cases, reference compounds were available
for comparison of retention times. In a few cases, at least for
a part of the observed TP, information from the studies on
metabolism and excretion from preclinical or clinical studies
could be useful for identification of TP. In one case, a TP
observed in a study on phototransformation proved helpful
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for identification of a TP from a water/sediment system.
However, often, completely different transformation path-
ways are observed in the environment as compared to human
or animal metabolism studies. An example is the different
transformation of the AI valsartan. In humans, hydroxylation
of the AI is observed (Steinhilber et al. 2010), whereas in the
environment, N-dealkylation and amide hydrolysis lead to a
different TP (Helbling et al. 2010; Kern et al. 2010).
Considering all available information, the following reaction
types were observed to occur in the above-mentioned
water/sediment systems: oxidation (formation of C–C dou-
ble bonds), hydrolysis (amide hydrolysis, ester hydrolysis),
dealkylation (N–, S–) and reduction (S atom). In none of the
studies has O-dealkylation been observed, as has already
been described by Wick et al. (2011). Wick et al. (2011) only
noticed little overlap between transformation pathways in
humans and in activated sludge. Löffler et al. (2005) exam-
ined a range of AI in OECD 308 studies and did not find
similarities between human ME and environmental TP from
water/sediment systems. Kern et al. (2010) examined four
different AI in batch experiments with activated sludge. Four
of the observed TP were identical to previously known human
ME, and three TP did not show similarities with human
metabolites. Therefore, information from metabolism studies
in humans or animals can be helpful when trying to identify
environmental TP, but they cannot be used to predict the
outcome of studies with environmentally relevant matrices.
Persistence of TP compared to the parent
For TP that are detected in amounts ≥10 % of the originally
applied amount of parent substance, according to OECD
guideline 308, not only is identification required but also
their pattern of formation and decline should be established,
which means that a kinetic model has to be fitted to the data
to derive a DT50 not only for the parent but also for the TP.
This was only accomplished in five of the studies. However,
it has to be considered that for eight studies, the amount of
TP was increasing towards the study end, and therefore,
deriving a DT50 was not possible. In these cases, prolonging
the study could have yielded valuable information on the
persistence of the TP.
As Fig. 2 illustrates, in 19 % of the studies were TP
observed showing a longer DT50 than the parent. For 26 %
of the AI, an evaluation of the DT50 is impossible because
towards the end of the studies, the concentration of TP is still
increasing or at least not showing a clearly declining trend.
Consequently, a DT50 cannot be derived. In summary, for
45 % of all AI, there are indications for an increase in DT50
for the TP compared to the parent.
The evaluation highlights that the kinetic fitting of the
data is a huge problem regarding the interpretation of the
results from simulation studies. Kinetic modelling is most
often difficult because too few sampling time points are
included in the studies. Recommendations on the evaluation
of simulation studies by the FOCUS group (2006) includes
that “… the number of sampling times and/or the experimen-
tal period may need to be extended, to establish the degra-
dation pathway and distribution between the water column
and sediment.…With metabolites [TP], additional sampling
points may be needed to estimate formation rates more
precisely, to reduce the influence of the statistical correlation
between estimated formation and degradation rates…”
Examples for kinetic fitting available on the FOCUS website
(2013) for TP include ten sampling time points. As the
evaluation shows, for persistent TP, kinetic modelling is
often also not possible because the study ends when there
are no indications for a decline in concentration of the TP. In
these cases, the study should be prolonged or a separate
study for the TP should be envisaged. Further difficulties
stem from the OECD 308 test system setup. As no clear
distinction between partitioning and transformation process-
es is feasible with the standard setup, fitting of a kinetic
model is complicated by the presence of the two compart-
ments water and sediment. Therefore, to gain information on
transformation of pharmaceutical AI in surface waters, stud-
ies according to OECD 309 (surface water with environmen-
tally relevant particle concentrations as test system without a
sediment compartment, OECD 2004) could be an alternative
worth exploring.
Comparison of OECD 301 and 308 type studies
Figure 3 shows data pairs for mineralisation observed in tests
according to OECD 301 on ready biodegradability (mostly
from OECD 301 B with CO2 evolution as endpoint) and
according to OECD 308 (transformation in water/sediment sys-
tems, CO2 evolution, other volatile gases were not observed).
Fig. 1 Detection and
identification in studies
conducted according to OECD
guideline 308 (water/sediment
systems)
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Mineralisation within 28 days from ready biodegradability stud-
ies and simulation studies is generally ≤20 %, underlining the
fact that small molecule pharmaceutical AI are predominantly
designed to be persistent, stable compounds. It is, however,
apparent that there is no correlation between the results of the
different studies. A linear regression would yield a correlation
coefficient of only 0.1. To interpret this observation, it is impor-
tant to consider what the data actually reflect. In tests on ready
biodegradability, ultimate biodegradation of the parent to CO2 is
measured, taking into account the whole molecule and each C
atom, whereas from the OECD 308 studies, only information on
the labelled part of the molecule is obtained. The results show
that the information derived fromOECD 308 studies differ from
the mineralisation unbiased by the labelling position as deter-
mined from OECD 301 studies. As pharmaceutical AI are often
relatively large, complexmolecules, labelling of one phenyl ring
or just one C atom is not enough to get results representative for
the whole molecule. This comparison can only be done directly
for mineralisation, but it indicates that also for other parameters
measured in OECD 308 studies—TP and NER—the same bias
has to be assumed that is obvious for mineralisation. The data
show that under- as well as overestimation of each parameter
may occur when relying on mineralisation results (or results for
NER or TP) from insufficiently labelled OECD 308 studies.
Besides the problems of representatively radio labelling AI, it is
difficult, costly and sometimes barely possible to synthesize
suitably 14C radio-labelledmaterial for semi-syntheticmolecules
like some antibiotic compounds. Consequently, using unlabelled
techniques, especially LC–MS/MS-based identification of TP
(Prasse et al. 2011;Wick et al. 2011; Stravs et al. 2013), might be
more appropriate for detection and identification of TP.
Case study: valsartan and its TP (val)sartan acid
Valsartan is an AI from the sartan class of antihypertensive
compounds acting on the AT1 subtype of the angiotensin II
receptor (Steinhilber et al. 2010). The class of sartans be-
longs to the highly consumed pharmaceutical AI (more than
150 t/year in Germany) with valsartan being the most con-
sumed compound (86 t/year in Germany, based on data for
2012 from IMS MIDAS®). Valsartan has been shown to be
transformed to a persistent TP in batch tests using activated
sludge (Helbling et al. 2010). The transformation pathway
has been elucidated and proceeds via N-dealkylation, subse-
quent amide hydrolysis and hydrolysis/oxidation to
(val)sartan acid (Helbling et al. 2010). The parent compound
has a short DT50 which would not lead to concerns about
persistence, whereas the TP (val)sartan acid shows a DT50
410 times longer than that of the parent (Helbling et al. 2010)
and consequently fulfils the vP criterion (ECHA 2012) with
a DT50 >60 days for the water compartment. The parent
valsartan has to be considered a mobile substance with a
Kd in the range 24–39 L/kg (Kern et al. 2010). As TP are
often more polar than their parent compounds, it has to be
assumed that (val)sartan acid is also a mobile compound.
Due to the high consumption of the parent, its unchanged
excretion from patients at about 90 % (Steinhilber et al.
2010), its very high persistence and potential mobility,
valsartan acid is likely to pose a risk for groundwater and
raw drinking water contamination when drinking water is
produced by bank filtration. Based on structural similarity,
also other compounds from the sartan class of compounds
could form the same TP in the environment. However, there
is no experimental evidence for a similar behaviour.
(Val)sartan acid has been measured in high concentrations
in the range of 1 μg/L in WWTP effluent (Kern et al. 2010).
In one of three sampled groundwater wells in Switzerland,
Fig. 2 Information on DT50
given for TP




















mineralisation (%) OECD 301
Fig. 3 Comparison of the amount of mineralisation (in percent) from
studies according to OECD 301 and OECD 308 after 28 days (n=29).
The dashed line represents a linear regression of percent mineralisation in
OECD 308 studies vs. OECD 301 studies (coefficient of correlation=0.1)
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concentrations of sartan acid in the low nanogram-per-litre
range (<10 ng/L) were measured. This well is probably
influenced by bank filtration from a nearby river (personal
communication, Eawag).
The case study of the AI valsartan and its persistent TP
(val)sartan acid highlights the fact that, in some cases, it is
important to consider TP in the assessment of the behaviour
of pharmaceutical AI in the environment as they might be the
more relevant compounds concerning exposure of environ-
mental compartments or the protection of water resources for
drinking water production.
Conclusions
The systematic evaluation of studies on biodegradation and
transformation in water/sediment systems shows that phar-
maceutical AI are commonly not readily biodegradable and
that TP are generally observed. In 45 % of the studies,
indications were found that TP show a longer DT50 than
the parent compounds. This highlights that only looking at
the parent compound is not always sufficient. For these cases
(and also cases where parent and TP show a high persistence),
TP have to be considered when assessing environmental
behaviour and effects of pharmaceuticals regarding (1) eco-
toxicological effects, (2) PBT assessment and (3) assessment
of persistent and mobile substances with a risk for groundwa-
ter or raw drinking water contamination. Especially in the
latter two cases, additional information might be required to
finalise an environmental risk assessment.
The quality of the studies concerning TP is variable.
There is a need for improvement in kinetic fitting especially
for TP. Screening for and identification of TP is often prob-
lematic and could benefit from rapid development of LC–
MS/MS techniques and databases for identification purposes
based solely on LC–MS spectra and application of these new
developments in routine analytical methods. Kinetic model-
ling could be aided by taking into account the recommenda-
tions given by FOCUS (2006), especially including more
sampling time points. Test systems like in OECD 309 with
low suspended solids concentration might be valuable for
assessing the environmental behaviour of pharmaceutical AI
in the aquatic compartment; however, there is a lack of expe-
rience with this test system. A more detailed understanding of
transformation processes for complex molecules like pharma-
ceuticals at environmentally relevant concentrations and un-
der environmentally relevant conditions could help to improve
study design and interpretation in the assessment of transfor-
mation and persistence of pharmaceuticals.
The case study on a persistent TP of the antihypertensive
AI valsartan clearly illustrates the fact that in some cases, TP
have to be considered separately from their parent com-
pounds with regard to their potential for groundwater/raw
drinking water contamination. In this respect, it should also be
kept in mind that, during drinking water production, some
treatment techniques may further transform persistent TP to
substances which exhibit (eco)toxicological effects. An exam-
ple is a toxic ozonation product formed from carboxyaciclovir,
a TP of the antiviral AI aciclovir (Prasse et al. 2012) that enters
raw drinking water because of its persistence and mobility, or
the toxic iodinated disinfection by-products formed in the
presence of persistent and mobile iodinated X-ray contrast
agents (Duirk et al. 2011).
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